Eculizumab
Brand name: Soliris
Rank #195 of 500 drugs by total cost
$74.6M
Total Cost
1,794
Total Claims
$74.6M
Total Cost
89
Prescribers
$42K
Cost per Claim
0
Beneficiaries
1,801
30-Day Fills
$838K
Avg Cost/Provider
20
Avg Claims/Provider
About Eculizumab
Eculizumab (sold as Soliris) was prescribed 1,794 times by 89 Medicare Part D providers in 2023, costing the program $74.6M. At $42K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 192 | Diltiazem Hcl (Diltiazem 24hr Er (Cd)) | $75.9M | 1,846,124 |
| 193 | Carvedilol (Carvedilol) | $75.6M | 6,390,691 |
| 194 | Cannabidiol (Cbd) (Epidiolex) | $75.5M | 15,726 |
| 195 | Eculizumab (Soliris) | $74.6M | 1,794 |
| 196 | Lidocaine (Lidocaine) | $74.4M | 416,864 |
| 197 | Simvastatin (Simvastatin) | $74.4M | 6,872,746 |
| 198 | Sertraline Hcl (Sertraline Hcl) | $74.3M | 6,472,210 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology